Académique Documents
Professionnel Documents
Culture Documents
KELAS :A
JURUSAN/FAKULTAS : FARMASI/FMIPA
Drug Interactions
Antipsychotics produce more important pharmacodynamic than pharmacokinetic interactions
because of their multiple effects.
Additive effects may occur when these drugs are combined with others that have sedative
effects, α-adrenoceptor–blocking action, anticholinergic effects, and—for thioridazine and
ziprasidone— quinidine-like action. A variety of pharmacokinetic interactions have been
reported, but none are of major clinical significance.
Overdoses
Poisonings with antipsychotic agents (unlike tricyclic antidepressants) are rarely fatal, with the
exception of those due to mesoridazine and thioridazine. In general, drowsiness proceeds to
coma, with an intervening period of agitation. Neuromuscular excitability may be increased and
proceed to convulsions. Pupils are miotic, and deep tendon reflexes are decreased. Hypotension
and hypothermia are the rule, although fever may be present later in the course. The lethal effects
of mesoridazine and thioridazine are related to induction of ventricular tachyarrhythmias.
Patients should be given the usual “ABCD” treatment for poisonings (see C hapter 58) and
treated supportively. Management of overdoses of thioridazine and mesoridazine, which are
complicated by cardiac arrhythmias, is similar to that for tricyclic antidepressants (see Chapter
30 ).
Patients with schizophrenia need psychosocial support based around activities of daily living,
including housing, social activities, returning to school, obtaining the optimal level of work they
may be capable of, and restoring social interactions. Unfortunately, funding for this crucial
component of treatment has been minimized in recent years. Case management and therapy
services are a vital part of the treatment program that should be provided to patients with
schizophrenia. Firstepisode patients are particularly needful of this support because they often
deny their illness and are noncompliant with medication.
remains a scientific mystery and a personal disaster for the patient. Although most schizophrenic
patients obtain some degree of benefit from these drugs—in some cases substantial benefit—
none are made well by them.
REFERENSI : Katzung G Bertram, Susan B Masters, Anthony J. Trevor, BASIC & CLINICAL
PHARMACOLOGY, Mc Graw Hill Medical, New York.